Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Octapharma
- 12 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 12 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 12 Oct 2017 Status changed from recruiting to active, no longer recruiting.